Screening Underway for Incannex's DReAMzz Phase 2 Sleep Apnea Trial
IXHL sits 23% above its 52-week low of $2.49 on light trading volume (0.4× avg).
Summary
Incannex Healthcare announced that participant screening has begun in its DReAMzz Phase 2 study of IHL-42X, an oral treatment for obstructive sleep apnea, advancing the lead program toward Phase III development.
Key Events · Product Development and Regulatory · IXHL
-
Participant Screening Begins
The first clinical sites are now approved and actively screening participants for the DReAMzz Phase 2 dose confirmation study of IHL-42X in obstructive sleep apnea.
-
Advancing Toward Phase III
Designed to optimize dosing, the study will generate data on objective sleep metrics and patient-reported outcomes to support regulatory approval and commercial differentiation.
-
FDA Fast Track Designation
IHL-42X previously received Fast Track status, enabling more frequent FDA interactions and a potentially expedited regulatory pathway.
-
Strong Prior Efficacy Data
Earlier Phase 2 results showed up to an 83% reduction in Apnea-Hypopnea Index and significant improvements in fatigue and sleep-related impairment.
Analysis · IXHL · Life Sciences
With the start of patient screening in its DReAMzz Phase 2 study of IHL-42X, Incannex takes a pivotal step toward Phase III development. The drug, which already holds FDA Fast Track designation, demonstrated up to an 83% reduction in apnea events in earlier trials. In a market affecting one billion people globally and still lacking any approved oral therapies for obstructive sleep apnea, this milestone keeps the program on track and reinforces the company's lead.
At the time of this filing, IXHL was trading at $3.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.3M. The 52-week trading range was $2.49 to $49.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.